Novel Bunya virus infection
Conditions
Interventions
control group:Follow the guidelines for symptomatic support treatment
experimental group:symptomatic treatment+Favipiravir
Sponsors
The First Affiliated Hospital of Anhui Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed in accordance with the prevention and treatment guidelines of Severe fever with thrombocytopenia syndrome (SFTS) issued by the Ministry of Health; 2. platelet count between (30~80)x10^9/L on admission; 3. aged between 18 to 80 years; 4. women of childbearing age or male subjects agree to take Take effective contraceptive measures within 90 days after the last admission of oral medicine to ensure the female subjects or male subjects partners are not pregnant; 5. subjects are willing to participate in the study and accept the randomization; 6. Not participated in any drug clinical trials before signing the written informed consent.
Exclusion criteria
Exclusion criteria: 1. judged by the investigator to be unsuitable to participate in this studye.g. Severe vomiting or difficulty taking medication; 2. The time interval between admission time and onset time was >7 days; 3. with hyperchloremic acidosis renal insufficiencyanuria or any other contraindications; 4. received systematic antiviral and immunoregulatory therapy 6 months before this study; 5. Co-infection with other pathogens, such as HBV, HCV, HIV or syphilis, or pathogens that cause similar symptoms, such as rickettsia, Lyme disease spirochetes or Babesia; 6. Patients with chronic underlying diseases such as cancer, tuberculosis or nephropathy; 7. Have recently taken antiplatelet drugs or antiallergic drugs; 8. pregnant or lactating women; 9. Patients participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| fatality rate;rate of severity;improvement rate;Virus clearance rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disappearance time of major clinical features;Days of Restoration of Thrombocyte and leucocyte;Incidence of severe complications;hemorrhage;immunological index; | — |
Countries
China
Contacts
Public ContactXihai XU
The First Affiliated Hospital of Anhui Medical University
Outcome results
None listed